ODDS VS PROBABILITA’ : UN MINUTO PER COMPRENDERE LA DIFFERENZA E PASSARE DALL’UNO ALL’ALTRA !

METODOLOGIA, REAL WORLD EVIDENCELascia un commento

Odds != Probability Keith McNulty (Expert and Author in Applied Mathematics, Data Science, Statistics and Psychometrics. Find me on LinkedIn or Twitter or drkeithmcnulty.com) Many people use the words ‘odds’ and ‘probability’ interchangeably. They are both terms that imply an estimate of likelihood or chance. I can understand this for laypeople, but I often see…

CARCINOMA EPATOCELLULARE: UNA REVISIONE ED UNA META-ANALISI DI GASTROENTEROLOGY SUI TRIAL DELL’ULTIMO VENTENNIO

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, LINEE GUIDA EBM, MEDICINA INTERNALascia un commento

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020) Philipp K. Haber et al. Background & Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous randomized controlled trials (RCTs) have aimed at improving outcomes across…

IPERTENSIONE PORTALE ED ASCITE. LE NUOVE LINEE GUIDA AISF EVIDENCE-BASED (PICO QUESTION) !

Senza categoriaLascia un commento

Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF) Portal hypertension and ascites are two crucial events in the natural history of liver cirrhosis, whose appearance marks a downward shift in the prognosis of the disease. Over the years, several international and national societies…

IL NUOVO RISCHIO CARDIOVASCOLARE “SCORE2 risk calculator”: UN INTERVISTA AL PRINCIPALE AUTORE, IL PROF. EMANUELE DI ANGELOANTONIO

MEDICI DI FAMIGLIA, MEDICINA INTERNA, METODOLOGIA, REAL WORLD EVIDENCELascia un commento

Global Spotlights A cardiovascular risk calculator to save millions of lives Mark Nicholls* It is a collaboration of about 200 investigators, including 45 cohorts in 13 countries with 700,000 participants, and has taken almost 2 years to create a meaningful cardiovascular risk score for the next 10 years. But arguably the most important number surrounding…

LO SVILUPPO DEL “TOOL” UpPRIORITY PER RIDURRE LO SPRECO DI META-ANALISI E LINEE GUIDA. QUALE PROBLEMA CLINICO MERITA ATTENZIONE? (2017)

METODOLOGIA, REAL WORLD EVIDENCELascia un commento

Development of a prioritisation tool for the updating of clinical guideline questions: the UpPriority Tool protocol Laura Martínez García  et al. Abstract Introduction: Due to a continuous emergence of new evidence, clinical guidelines (CGs) require regular surveillance of evidence to maintain their trustworthiness. The updating of CGs is resource intensive and time consuming; therefore, updating may…

IL MODELLO UpPRIORITY E’ DI GRANDE UTILITA’ PER IDENTIFICARE LE AREE DI RICERCA DI META-ANALISI E LINEE GUIDA.

METODOLOGIA, REAL WORLD EVIDENCELascia un commento

The UpPriority tool supported prioritization processes for updating clinical guideline questions Andrea Juliana Sanabria et al.   Abstract Objective: We aim to 1) use the UpPriority tool to identify which clinical questions (CQs) within the clinical guidelines (CGs) need to be prioritized for updating and 2) assess the implementation of the tool in a real-world set of…